Antibody engineers seek optimal drug targeting TIGIT checkpoint
Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.
Gespeichert in:
| Veröffentlicht in: | Nature biotechnology 2020-09, Vol.38 (9), p.1007-1009 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1009 |
|---|---|
| container_issue | 9 |
| container_start_page | 1007 |
| container_title | Nature biotechnology |
| container_volume | 38 |
| creator | Dolgin, Elie |
| description | Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action. |
| doi_str_mv | 10.1038/s41587-020-0666-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2440466769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A634552836</galeid><sourcerecordid>A634552836</sourcerecordid><originalsourceid>FETCH-LOGICAL-c623t-67204567db26a4d78e452241d7a7ae0382c45ead8ba68bc59d2cbd4a2bff7f993</originalsourceid><addsrcrecordid>eNqN0l9r1TAYBvAiCs7pB_CuIIgDO5M0f9orOQw3DwwGevQ2pMnbLltPckxScN9-KRVmxYkU2pD-njZpn6J4jdEpRnXzIVLMGlEhgirEOa_wk-IIM5oHvOVP8xjNdzHjz4sXMd4ghDjl_Kj4uHHJdt7cleAG6wBCLCPAbekPye7VWJowDWVSYYBk3VDuthfbXamvQd8evHXpZfGsV2OEV7-ux8W380-7s8_V5dXF9mxzWWlO6lRxQRBlXJiOcEWNaIAyQig2QgkFeQNEUwbKNJ3iTadZa4juDFWk63vRt219XLxbnnsI_scEMcm9jRrGUTnwU5SEUpQ3JPhM3_xBb_wUXF5dViIT3CL6b0URwVi09YMa1AjSut6noPT8arnhNWWMNDXP6vQvKh8G9lZ7B73N86vA21UgmwQ_06CmGOUanjwOt1-__L-9-r6273-z3RTzr4_5FO1wneISWXG8cB18jAF6eQi5HeFOYiTn_smlfzL3T879kzhnyJKJ2boBwsMHfjx0D-Ae1ro</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2440211793</pqid></control><display><type>article</type><title>Antibody engineers seek optimal drug targeting TIGIT checkpoint</title><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>Dolgin, Elie</creator><creatorcontrib>Dolgin, Elie</creatorcontrib><description>Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/s41587-020-0666-1</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Agriculture ; Antibodies ; Apoptosis ; Bioinformatics ; Biological products industry ; Biomedical and Life Sciences ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biopharmaceutics ; Biotechnology ; Drug targeting ; Engineers ; Health aspects ; Immunoglobulin G ; Life Sciences ; Methods ; Monoclonal antibodies ; News ; Product development ; T cells ; Testing ; Therapeutic targets</subject><ispartof>Nature biotechnology, 2020-09, Vol.38 (9), p.1007-1009</ispartof><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2020</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2020.</rights><rights>Copyright Nature Publishing Group Sep 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c623t-67204567db26a4d78e452241d7a7ae0382c45ead8ba68bc59d2cbd4a2bff7f993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41587-020-0666-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41587-020-0666-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids></links><search><creatorcontrib>Dolgin, Elie</creatorcontrib><title>Antibody engineers seek optimal drug targeting TIGIT checkpoint</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><description>Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.</description><subject>Agriculture</subject><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Bioinformatics</subject><subject>Biological products industry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biopharmaceutics</subject><subject>Biotechnology</subject><subject>Drug targeting</subject><subject>Engineers</subject><subject>Health aspects</subject><subject>Immunoglobulin G</subject><subject>Life Sciences</subject><subject>Methods</subject><subject>Monoclonal antibodies</subject><subject>News</subject><subject>Product development</subject><subject>T cells</subject><subject>Testing</subject><subject>Therapeutic targets</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>N95</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0l9r1TAYBvAiCs7pB_CuIIgDO5M0f9orOQw3DwwGevQ2pMnbLltPckxScN9-KRVmxYkU2pD-njZpn6J4jdEpRnXzIVLMGlEhgirEOa_wk-IIM5oHvOVP8xjNdzHjz4sXMd4ghDjl_Kj4uHHJdt7cleAG6wBCLCPAbekPye7VWJowDWVSYYBk3VDuthfbXamvQd8evHXpZfGsV2OEV7-ux8W380-7s8_V5dXF9mxzWWlO6lRxQRBlXJiOcEWNaIAyQig2QgkFeQNEUwbKNJ3iTadZa4juDFWk63vRt219XLxbnnsI_scEMcm9jRrGUTnwU5SEUpQ3JPhM3_xBb_wUXF5dViIT3CL6b0URwVi09YMa1AjSut6noPT8arnhNWWMNDXP6vQvKh8G9lZ7B73N86vA21UgmwQ_06CmGOUanjwOt1-__L-9-r6273-z3RTzr4_5FO1wneISWXG8cB18jAF6eQi5HeFOYiTn_smlfzL3T879kzhnyJKJ2boBwsMHfjx0D-Ae1ro</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Dolgin, Elie</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>AAYXX</scope><scope>CITATION</scope><scope>N95</scope><scope>XI7</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20200901</creationdate><title>Antibody engineers seek optimal drug targeting TIGIT checkpoint</title><author>Dolgin, Elie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c623t-67204567db26a4d78e452241d7a7ae0382c45ead8ba68bc59d2cbd4a2bff7f993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Agriculture</topic><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Bioinformatics</topic><topic>Biological products industry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biopharmaceutics</topic><topic>Biotechnology</topic><topic>Drug targeting</topic><topic>Engineers</topic><topic>Health aspects</topic><topic>Immunoglobulin G</topic><topic>Life Sciences</topic><topic>Methods</topic><topic>Monoclonal antibodies</topic><topic>News</topic><topic>Product development</topic><topic>T cells</topic><topic>Testing</topic><topic>Therapeutic targets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dolgin, Elie</creatorcontrib><collection>CrossRef</collection><collection>Gale Business: Insights</collection><collection>Business Insights: Essentials</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dolgin, Elie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody engineers seek optimal drug targeting TIGIT checkpoint</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><date>2020-09-01</date><risdate>2020</risdate><volume>38</volume><issue>9</issue><spage>1007</spage><epage>1009</epage><pages>1007-1009</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><doi>10.1038/s41587-020-0666-1</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0156 |
| ispartof | Nature biotechnology, 2020-09, Vol.38 (9), p.1007-1009 |
| issn | 1087-0156 1546-1696 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2440466769 |
| source | Nature Journals Online; SpringerLink Journals - AutoHoldings |
| subjects | Agriculture Antibodies Apoptosis Bioinformatics Biological products industry Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biopharmaceutics Biotechnology Drug targeting Engineers Health aspects Immunoglobulin G Life Sciences Methods Monoclonal antibodies News Product development T cells Testing Therapeutic targets |
| title | Antibody engineers seek optimal drug targeting TIGIT checkpoint |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T19%3A18%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20engineers%20seek%20optimal%20drug%20targeting%20TIGIT%20checkpoint&rft.jtitle=Nature%20biotechnology&rft.au=Dolgin,%20Elie&rft.date=2020-09-01&rft.volume=38&rft.issue=9&rft.spage=1007&rft.epage=1009&rft.pages=1007-1009&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/s41587-020-0666-1&rft_dat=%3Cgale_proqu%3EA634552836%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2440211793&rft_id=info:pmid/&rft_galeid=A634552836&rfr_iscdi=true |